LakeShore Biopharma Co., Ltd (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company focused on vaccines and therapeutic biologics for infectious diseases and cancer, announced that its shareholders have approved the merger agreement at an extraordinary general meeting held today. The approval marks a significant step toward the company's transition to a privately held entity.
At the EGM, approximately 92.3% of the company's total outstanding ordinary shares as of the record date of May 27, 2026, were voted in person or by proxy. The merger agreement, along with the plan of merger and related transactions, received approval from approximately 86.2% of the total votes cast. The merger agreement, originally dated November 4, 2025, and amended on April 29, 2026, involves LakeShore Biopharma, Oceanpine Skyline Inc. (Parent), and Oceanpine Merger Sub Inc. (Merger Sub), a wholly owned subsidiary of Parent. Under the terms, Merger Sub will merge with and into LakeShore Biopharma, with the company continuing as the surviving entity and becoming a wholly owned subsidiary of Parent.
The completion of the merger is subject to the satisfaction or waiver of conditions specified in the merger agreement. If consummated, the company's shares and warrants will no longer be listed on any public marketplace, including the OTC Pink tier of the OTC Markets, and will cease to be registered under Section 12 of the Securities Exchange Act of 1934. This move will take LakeShore Biopharma private, removing it from public investor scrutiny and reporting requirements.
This development matters because it signals a strategic shift for LakeShore Biopharma, which has been working to advance its proprietary PIKA® immunomodulating technology platform and develop vaccines for rabies, hepatitis B, influenza, and other viral infections. Going private may allow the company to focus on long-term research and development without the pressure of quarterly earnings reports and public market volatility. For the industry, this trend of biopharmaceutical companies going private could indicate a growing preference for operational flexibility and capital allocation away from public markets. Investors holding shares or warrants will need to monitor the merger's completion and any potential compensation or exchange of securities as outlined in the merger agreement.
The company plans to work with the other parties to finalize the merger in due course. Forward-looking statements in the press release highlight risks and uncertainties, including the possibility that the merger may not occur if conditions are not met or waived. Additional information about these risks is available in the company's filings with the U.S. Securities and Exchange Commission (SEC), as well as the Schedule 13E-3 and proxy statement filed by the company.
For more information about LakeShore Biopharma, visit https://investors.lakeshorebio.com/.
